Neurogene Inc. announced the appointment of Julie Jordan, M.D., as Chief Medical Officer. Dr. Jordan brings to Neurogene over 20 years of industry and clinical expertise involving the design and execution of global clinical trials across multiple development areas, including gene therapy and central nervous system disorders. She most recently served as Chief Medical Officer of Homology Medicines, a clinical-stage company advancing gene therapies for the treatment of rare diseases.

In her prior role as Chief Medical Officer of Homology Medicines, Dr. Jordan was responsible for leading clinical development and operations, leading regulatory interactions and supporting translational research programs for the company's pipeline of gene therapy and gene editing candidates for rare diseases. Prior to assuming her role as Chief Medical Officer, Dr. Jordan served as the company's Senior Vice President, Head of Clinical Development and Operations. During her tenure, she successfully drove development and navigated regulatory challenges for multiple first-in-class genetic medicines, built and led a team of functional experts across multiple disciplines, and played a key role in strengthening relationships with patient advocacy groups and key opinion leaders.

Before joining Homology Medicines, she held global leadership roles of increasing responsibility for central nervous system, neuropsychiatry, and other programs at Cerevel Therapeutics, Avanir Pharmaceuticals and Teva Pharmaceutical Industries. Before joining industry, Dr. Jordan was a practicing physician for 10 years and previously served as Clinical Instructor of Medicine at Harvard Medical School and in the Department of Medicine at Massachusetts General Hospital (MGH). She holds an A.B. in Biology from Harvard College and an M.D. from Harvard Medical School and completed her residency in Internal Medicine at MGH, Harvard Medical School.